We are funding further vital research: John Goldman Fellowships 2020 At Leukaemia UK, we remain committed to funding crucial research into leukaemia and other blood cancers, even during this unprecedented time which is affecting so many aspects of our lives. Every 16 minutes someone is diagnosed with blood cancer in the UK. Blood cancer is the 3rd biggest cancer killer in the UK. The high prevalence of blood cancers reinforce our drive to find better care and treatments for those affected. Despite this pandemic which is having an effect on so many charities' ability to fund research, we are delighted to announce that we are funding more ground-breaking research: our prestigious John Goldman Fellowships 2020. Our John Goldman Fellowships – created in 2015 in honour of world-renowned haematologist Professor John Goldman (1938-2013), nurture the next generation of scientific talent in their early careers, providing up to £125,000 for up to two years. Through these Fellowships, we empower promising doctors and scientists to become the scientific leaders of tomorrow, giving them the opportunity to collect the data needed to prove the validity of theories, a crucial step towards our aim of curing leukaemia and other blood cancers. We are pleased to fund a total of five John Goldman Fellowships 2020 and will be announcing these as soon as they are confirmed, adding them to the list below. John Goldman Fellows 2020: 1. Leukaemia: Understanding premalignant stages Researcher: Dr Miguel Ganuza, Queen Mary University of London and John Goldman Fellow 2020 This research will provide a better understanding of the premalignant stages of leukaemia and new means to prevent and block their progression into more advanced leukaemia. 2. AML: Understanding gene activation to find novel therapeutic targets Researcher: Dr Bettina Wingelhofer- University of Manchester and John Goldman Fellow 2020 This research will help us understand how the complex network of interactions between enhancers and genes work, allowing us to identify novel regulators of AML which could be used for therapeutic targeting with the aim of saving more patients from this devastating condition. 3. Lymphoma: Using “virtual patients” to find new ways to treat diffuse large B-cell lymphoma Researcher: Dr Simon Mitchell, University of Sussex and John Goldman Fellow 2020 Current treatments for diffuse large B-cell lymphoma (DLBCL) are effective, but they won’t work for some patients. Every patient’s DLBCL is different and by simulating the disease in the computer, Dr Mitchell aims to find promising new treatments that will be targeted to the Achilles' heel of each patient’s disease. 4. AML: Development and characterisation of a new class of drugs targeting the RNA methyltransferase METTL3 Researcher: Dr Kostas Tzelepis, University of Cambridge and John Goldman Fellow 2020 Acute myeloid leukaemia (AML) is an aggressive type of blood cancer. Despite scientific progress in understanding how this cancer develops, the mainstream therapies for AML have remained unchanged for decades. Dr Tzelepis's research has promising clinical potential to develop new therapeutic options, giving hope to patients with AML and other types of cancer. Find out more about our ground-breaking research and care projects. Read about our project, that as part of our IMPACT Clinical Trials Partnership, we are now working with Great Ormond Street Hospital to study patients who have had a stem cell transplant in the past and have severe COVID-19. This study will see how these individuals respond to treatment and how this can be improved for this very vulnerable group. Leukaemia UK relies completely on voluntary donations. Please help us support people affected by leukaemia and other blood cancers by donating to Leukaemia UK today, by fundraising or getting involved in our events.